Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Consolidation in Multiple Myeloma
NCT00416273Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2006
- Primary completion
- May 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Dec 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00416273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416273.